Switch theme
Sign up to access all valuation multiples
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
1988
18
Last FY Revenue n/a
LTM EBITDA -$3.8M
$4.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vivesto has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$3.8M.
In the most recent fiscal year, Vivesto achieved revenue of n/a and an EBITDA of -$3.6M.
Vivesto expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vivesto valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.8M | XXX | -$3.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$4.2M | XXX | -$4.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.0M | XXX | -$4.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Vivesto's stock price is SEK 0 (or $0).
Vivesto has current market cap of SEK 125M (or $13.0M), and EV of SEK 46.8M (or $4.9M).
See Vivesto trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9M | $13.0M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Vivesto has market cap of $13.0M and EV of $4.9M.
Vivesto's trades at n/a EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Vivesto's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vivesto has a P/E ratio of -3.2x.
See valuation multiples for Vivesto and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.0M | XXX | $13.0M | XXX | XXX | XXX |
| EV (current) | $4.9M | XXX | $4.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.2x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVivesto's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
Vivesto's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vivesto's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vivesto and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivesto acquired XXX companies to date.
Last acquisition by Vivesto was XXXXXXXX, XXXXX XXXXX XXXXXX . Vivesto acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vivesto founded? | Vivesto was founded in 1988. |
| Where is Vivesto headquartered? | Vivesto is headquartered in Sweden. |
| How many employees does Vivesto have? | As of today, Vivesto has 18 employees. |
| Who is the CEO of Vivesto? | Vivesto's CEO is Mr. Erik Kinnman, M.D.. |
| Is Vivesto publicy listed? | Yes, Vivesto is a public company listed on STO. |
| What is the stock symbol of Vivesto? | Vivesto trades under VIVE ticker. |
| When did Vivesto go public? | Vivesto went public in 2005. |
| Who are competitors of Vivesto? | Similar companies to Vivesto include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vivesto? | Vivesto's current market cap is $13.0M |
| Is Vivesto profitable? | Yes, Vivesto is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vivesto? | Vivesto's last 12 months EBITDA is -$3.8M. |
| What is the current EV/EBITDA multiple of Vivesto? | Current EBITDA multiple of Vivesto is -1.3x. |
| What is the current FCF of Vivesto? | Vivesto's last 12 months FCF is -$4.9M. |
| What is the current EV/FCF multiple of Vivesto? | Current FCF multiple of Vivesto is -1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
